Disease eradication in the 21st century: Implications for global health

Disease Eradication in the 21st Century: Implications for Global Health

Volumn , Issue , 2011, Pages 1-319

  Cochi, Stephen L ^a   Dowdle, Walter R ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Task Force for Global Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895586223     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (407)

1. Ahmad, K. 2003. Tsetse eradication programme under fi re. Lancet Infect. Dis. 3(1):4.
2. Ahorlu, C., S. Dunyo, E. Afrai, K. Koram, and F. Nkrumah. 1997. Malaria-related beliefs and behaviour in southern Ghana: Implications for treatment, prevention and control. Trop. Med. Intl. Health 2(5):488-499
3. Alexander, L. N., J. F. Seward, T. A. Santibanez, et al. 2004. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 292(14):1696-1701
4. Amazigo, U. V. 2008. The African Programme for Onchocerciasis Control (APOC). Ann. Trop. Med. Parasitol. 102(1):19-22.
5. Anderson, R. M., and R. May. 1991. Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford Univ. Press.
6. Andreasen, A., and P. Kotler. 2008. Strategic Marketing for Nonprofi t Organizations, 7th ed. Saddle River, NJ: Pearson Education, Inc.
7. Andrews, J. M., and A. D. Langmuir. 1963. The philosophy of disease eradication. Am. J. Public Health 53:1-6.
8. Andrus, J. K., C. A. de Quadros, and C. Castillo-Solórzano. 2011a. Chapter 54: Measles. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, ed. R. L. Guerrant et al. New York: Saunders, in press.
9. Andrus, J. K., C. A. de Quadros, C. Castillo-Solórzano, M. Roses Periago, and D. A. Henderson. 2011b. Measles and rubella eradication in the Americas. Vaccine: in press.
10. Andrus, J. K., C. A. de Quadros, C. Ruiz Matus, S. Luciani, and P. Hotez. 2009. New vaccines for developing countries: Will it be feast or famine? Am. J. Law Medicine 35:311-322.
11. Andrus, J. K., V. Dietz, J. W. Fitzsimmons, and C. Castillo-Solórzano. 2006. Accelerating policy, deployment, and access to new and underutilized vaccines in developing countries. Harvard Health Policy Rev. 7(2):91-101.
12. Andrus, J. K., A. M. Ropero, G. Ghisays, et al. 2010. Yellow fever and health diplomacy. In: Negotiating and Navigating Global Health: Case Studies in Global Health Diplomacy, ed. E. Rosskam and I. Kickbusch. London: World Scientifi c, Imperial College Press.
13. Andrus, J. K., and M. Roses Periago. 2004. Elimination of rubella and congenital rubella syndrome in the Americas: Another opportunity to address inequities in health. Pan. Am. J. Public Health 15:145-146.
14. APOC. 2009. Community directed treatment with ivermectin (CDTI). www.who.int/ apoc/cdti/en (accessed 17 February 2011).
15. Arora, N. K., S. Chaturvedi, and R. Dasgupta. 2010. Global lessons from India's poliomyelitis elimination campaign. Bull. WHO 88(3):161-240.
16. Arora, N. K., A. K. Patwari, and M. Lakshman, eds. 1999. Pulse Polio Immunization Program Evaluation 1997-1998. New Delhi: All India Institute of Medical Sciences.
17. Atun, R., S. Bennett, and A. Duran. 2008. When do vertical (stand-alone) programmes have a place in health systems? Policy brief written for the WHO European Ministerial Conference on Health Systems, June 25-27, 2008, Tallinn, Estonia.http://www.euro.who.int/__data/assets/pdf_fi le/0008/75491/E93417.pdf (accessed 11 October 2010).
18. Atun, R., T. de Jongh, F. Secci, K. Ohiri, and O. Adeyi. 2010. Integration of targeted health interventions into health systems: A conceptual framework for analysis. Health Policy Plan. 25:104-111.
19. Atun, R., N. Lennox-Chhugani, F. Drobniewski, Y. A. Samyshkin, and R. J. Coker. 2004. A framework and toolkit for capturing the communicable disease programmes within health systems: Tuberculosis control as an illustrative example. Eur. J. Public Health 14(3):267-273.
20. Auld, M. C. 2003. Choices, beliefs, and infectious disease dynamics. J. Health Econ. 22(3):361-377.
21. Aylward, R. B., A. Acharya, S. England, M. Agocs, and J. Linkins. 2003. Global health goals: Lessons from the worldwide effort to eradicate poliomyelitis. Lancet 362(9387):909-914.
22. Aylward, R. B., K. A. Hennessey, N. Zagaria, J. M. Olivé, and S. L. Cochi. 2000a. When is a disease eradicable? 100 years of lessons learned. Am. J. Public Health 90:1515-1520.
23. Aylward, R. B., H. F. Hull, S. L. Cochi, et al. 2000b. Disease eradication as a public health strategy: A case study of poliomyelitis eradication. Bull. WHO 78:285-297.
24. Aylward, R. B., and J. Linkins. 2005. Polio eradication: Mobilizing and managing the human resources. Bull. WHO 83(4):268-273.
25. Aylward, R. B., R. W. Sutter, S. L. Cochi, et al. 2006. Risk management in a polio-free world. Risk Analysis 26:1441-1448.
26. Barrett, S. 2003. Global disease eradication. J. Eur. Econ. Assoc. 1(2/3):591-600.
27. Barrett, S. 2004. Eradication versus control: The economics of global infectious disease policies. Bull. WHO 82:683-688.
28. Barrett, S. 2006. The smallpox eradication game. Public Choice 130(1-2):179-207.
29. Barrett, S. 2007. Why Cooperate? The Incentive to Supply Global Public Goods. Oxford: Oxford Univ. Press.
30. Barrett, S. 2009. Polio eradication: Strengthening the weakest links. Health Affairs 28(4):1079-1090.
31. Barrett, S., and M. Hoel. 2003. Optimal Disease Eradication. Oslo: Health Economics Research Programme, Univ. of Oslo.
32. Barrett, S., and M. Hoel. 2007. Optimal disease eradication. Env. Dev. Econ. 12:627-652.
33. Bauch, C. T., and D. J. D. Earn. 2004. Vaccination and the theory of games. PNAS 101(36):13,391-13,394.
34. Bauch, C. T., A. P. Galvani, and D. J. D. Earn. 2003. Group interest versus self-interest in smallpox vaccination policy. PNAS 100(18):10,564-10,567.
35. Beauchamp, D. E. 2007. Community: The neglected tradition of public health. In: Public Health Ethics: Theory, Policy, and Practice, ed. R. Bayer et al., pp. 45-56. Oxford: Oxford Univ. Press.
36. Béhague, D. P., and K. T. Storeng. 2008. Collapsing the vertical-horizontal divide: An ethnographic study of evidence-based policymaking in maternal health. Am. J. Public Health 98(4):644-649.
37. Beutels, P., W. J. Edmunds, and R. D. Smith. 2008. Partially wrong? Partial equilibrium and the economic analysis of public health emergencies of international concern. Health Econ. 17(11):1317-1322.
38. Bhattacharya, S., and R. Dasgupta. 2009. A tale of two global health programs: Smallpox eradication's lessons for the antipolio campaign in India. Am. J. Public Health 99(7):1176-1184.
39. Bhutta, Z. A., S. Ali, S. Cousens, et al. 2008. Alma-Ata: Rebirth and Revision 6. Interventions to address maternal, newborn, and child survival: What difference can integrated primary health care strategies make? Lancet 372:972-989.
40. Black, R. E., S. S. Morris, and J. Bryce. 2003. Where and why are 10 million children dying every year? Lancet 361:2226-2234.
41. Blacklock, D. B. 1926. The development of Onchocerca volvulus in Simulium damnosum. Ann. Trop. Med. Parasitol. 20:1-48.
42. Blenko, M., M. Mankins, and P. Rogers. 2010. The decision-driven organization. Harvard Bus. Rev. 88(6):54-62.
43. Bloch, A. B., W. A. Orenstein, H. C. Stetler, et al. 1985. Health impact of measles vaccination in the United States. Pediatrics 76:524-532.
44. Bloom, D. E. 2007. Governing global health. Finance & Devel. 44:31-35.
45. Boatin, B. 2008. The onchocerciasis control program in West Africa (OCP). Ann. Trop. Med. Parasitol. 102(1):1317.
46. Braber, K. L. 2004. An evaluation of GAEL, the Global Alliance for the Elimination of Leprosy. Leprosy Rev. 75:208-213.
47. Bradley, D. J. 1998. The particular and the general: Issues of specifi city and verticality in the history of malaria control. Parassitologia 40(1-2):5-10.
48. Brandach, J. 1996. Organizational Alignment: The 7-S Model. Boston: Harvard Business School Publishing.
49. Brisson, M., and W. J. Edmunds. 2003. Economic evaluation of vaccination programs: The impact of herd-immunity. Med. Decis. Making 23(1):76-82.
50. Broekmans, J. F., G. B. Migliori, and H. L. Rieder. 2002. European framework for tuberculosis control and elimination in countries with a low incidence: Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur. Respir. J. 19:765-775.
51. Bryce, J., K. Gilroy, G. Jones, et al. 2010. The Accelerated Child Survival and Development programme in west Africa: A retrospective evaluation. Lancet 375:572-582.
52. Buse, K., and A. M. Harmer. 2007. Seven habits of highly effective global publicprivate health partnerships: Practice and potential. Soc. Sci. Med. 64(2):259-271.
53. Bush, K. 2000. Polio, war and peace. Bull. WHO 78:281-282.
54. Cairncross, S., F. Cutts, and H. Periés. 1997. Dracunculiasis eradication. Lancet 350(9080):812-813.
55. Caplan, A. 2009. Is disease eradication ethical? Lancet 373:2192.
56. Carter Center. 2010. International Task Force. http://www.cartercenter.org/health/itfde/ index.html (accessed 23 October 2010).
57. Cassels, A. 1997. A Guide to Sector-wide Approaches for Health Development: Concepts, Issues and Working Arrangements. Geneva: WHO.
58. Castillo-Solórzano, C., and J. K. Andrus. 2004. Rubella elimination and improving health care for women. Emerg. Infect. Dis. 10:2017-2021.
59. Castillo-Solórzano, C., and C. A. de Quadros. 2002. Accelerated rubella control and the prevention of congenital rubella syndrome. Pan Am. J. Public Health 11(4):273- 276.
60. Castillo-Solórzano, C., C. Marsigli, P. Bravo Alcantara, et al. 2008. Progress toward elimination of rubella and congenital rubella syndrome: The Americas, 2003-2008. MMWR 57(43):1176-1179.
61. Cavalli, A., S. I. Bamba, M. N. Traore, et al. 2010. Interactions between global health initiatives and country health systems: The case of a neglected tropical diseases control program in Mali. PLoS Negl. Trop. Dis. 4(8):e798.
62. CDC. 1993a. Initial therapy for tuberculosis in the era of multidrug resistance: Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 42(RR-7):1.
63. CDC. 1993b. Recommendations of the International Task Force for disease eradication. MMWR 42(RR-16):1-38.
64. CDC. 1996. Progress toward the elimination of neonatal tetanus: Egypt, 1988-1994. MMWR 45(04):89-92.
65. CDC. 1998. Progress toward the elimination of tuberculosis: United States, 1998. MMWR 48(33):732-736.
66. CDC. 1999a. Global disease elimination and eradication as public health strategies. MMWR 48(Suppl):1-211.
67. CDC. 1999b. The principles of disease elimination and eradication. MMWR 48(Suppl 1):23-27.
68. CDI Study Group. 2010. Community-directed interventions for priority health problems in Africa: Results of a multicountry study. Bull. WHO 88(7):509-518.
69. Cello, J., A. V. Paul, and E. Wimmer. 2002. Chemical dynthesis of poliovirus cDNA: Generation of infectious virus in the absence of natural template. Science 297:1016- 1018.
70. Chan, M. 2008. The Case for Completing Polio Eradication. Geneva: WHO Report.
71. Chan, M. 2010. Time to get back on track to meet the millennium development goals. Opening address, Director-General of WHO. http://www.who.int/dg/speeches/2010/ WHA_address_20100517/en/index.html (accessed 21 October 2010).
72. Chen, L. C., and G. Berlinguer. 2001. Health equity in a globalizing world. In: Challenging Inequities in Health: From Ethics to Action, ed. T. Evans. Oxford: Oxford Univ. Press.
73. Chu, B. K., P. J. Hooper, M. Bradley, D. A. McFarland, and E. A. Ottesen. 2010. The economic benefi ts resulting from the fi rst 8 years of the global programme to eliminate lymphatic fi lariasis (2000-2007). PLoS Negl. Trop. Dis. 4(6):e708.
74. Cialdini, R. 2001. Harnessing the science of persuasion. Harvard Bus. Rev. October:72-79.
75. Clements, C. J., and F. T. Cutts. 1995. The epidemiology of measles: Thirty years of vaccination. Curr. Topics Microbiol. 191:13-33.
76. Cochi, S. L., C. A. de Quadros, S. Dittman, et al. 1998. What are the societal and political criteria for eradication? In: The Eradication of Infectious Diseases, ed. W. R. Dowdle and D. R. Hopkins, pp. 157-175. Dahlem Workshop Report, J. Lupp, series ed. Chichester: John Wiley & Sons.
77. Coles, J. 2006. Blindness and the Visionary: The Life and Work of Sir John Wilson. London: Giles de la Mar Publishing.
78. Collins, J. 2001. Level 5 Leadership. Harvard Bus. Rev. January:67-76.
79. Creese, A. L., and R. H. Henderson. 1980. Cost-benefi t analysis and immunization programmes in developing countries. Bull. WHO 58(3):491-497.
80. Crisp, G. 1956. Simuluium and Onchocerciasis in the Northern Territories of the Gold Coast. London: British Empire Society for the Blind.
81. Cummings, T., and C. Worley. 1996. Organizational Development and Change, p. 467. Boston: Southwestern College Publishing.
82. Cutting, W. A. M. 1980. Cost-benefi t evaluations of vaccination programmes. Lancet 2(8195):634-636.
83. Cutts, F. T., and L. E. Markowitz. 1994. Successes and failures in measles control. J. Infect. Dis. 170(Suppl 1):S32-S41.
84. Dabbagh, A., M. Gacic-Dobo, and E. Simons. 2009. Global measles mortality, 2000- 2008. MMWR 58(47):1321-1326.
85. Dadzie, Y., M. Neira, and D. Hopkins. 2003. Final report of the conference on the eradicability of onchocerciasis. Filaria J. 2:2.
86. Danovaro-Holiday, M. C., A. M. Ropero, and J. K. Andrus. 2008. Progress in vaccination against Hemophilus infl uenzae type b in the Americas. PLoS Med. 5(4):e87.
87. Dawson, A. 2009. Transparency, accountability and vaccination policy. J. Med. Ethics 35(5):274.
88. Dentzer, S. 2008. Past, present and future partnerships in disease elimination and eradication. The Carter Center. http://www.gsk.com/community/fi lariasis/ downloads/Partnerships-in-disease-elimination-Report.pdf (accessed 23 October 2010).
89. de Quadros, C. A., J. K. Andrus, M. C. Danovaro-Holliday, and C. Castillo-Solórzano. 2008. Feasibility of global measles eradication after interruption of transmission in the Americas. Expert Rev. Vaccines 7(3):355-362.
90. de Quadros, C. A., J. M. Olive, B. S. Hersh, et al. 1996. Measles elimination in the Americas: Evolving strategies. JAMA 13:224-229.
91. DeRoeck, D. 2004. The importance of engaging policy-makers at the outset to guide research on and introduction of vaccines: The use of policy-maker surveys. J. Health Popul. Nutr. 22(3):322-330.
92. De Serres, G., N. J. Gay, and C. P. Farrington. 2000. Epidemiology of transmissible diseases after elimination. Am. J. Epidemiol. 151:1039-1048.
93. DFID. 2007. The international health partnership. http://webarchive.nationalarchives. gov.uk/+/http://www.dfid.gov.uk/Media-Room/News-Stories/2007/The-International-Health-Partnership-Launched-Today/ (accessed 1 December 2010).
94. Dias, J. C. 2007. Southern Cone Initiative for the elimination of domestic populations of Triatoma infestans and the interruption of transfusional Chagas disease. Historical aspects, present situation, and perspectives. Memórias do Instituto Oswaldo Cruz 102(Suppl. 1):11-8.
95. Dias, J. C. 2009. Elimination of Chagas disease transmission: Perspectives. Memórias do Instituto Oswaldo Cruz 104:41-45.
96. Diawara, L., M. O. Traoré, A. Badji, et al. 2009. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: First evidence from studies in Mali and Senegal. PLoS Negl. Trop. Dis. 3(7):e497.
97. Dobson, M. 2007. Disease: The Extraordinary Stories Behind History's Deadliest Killers. London: Quercus Publishing Plc.
98. Donnelly, M. J., B. C. Herold, S. G. Jenkins, and R. S. Daum. 2003. Obstacles to the elimination of Haemophilus infl uenzae type b disease: Three illustrative cases. Pediatrics 112(6):1465-1466.
99. Dowdle, W. R. 1998. The principles of disease elimination and eradication. Bull. WHO 76(2):22-25.
100. Dowdle, W. R., and D. R. Hopkins, eds. 1998. The Eradication of Infectious Diseases. Dahlem Workshop Report, J. Lupp, series ed. Chichester: John Wiley & Sons.
101. Drucker, P. 2001. The Essential Drucker. New York: HarperCollins.
102. Duintjer Tebbens, R. J., M. A. Pallansch, S. L. Cochi, et al. 2011. Economic analysis of the global polio eradication initiative. Vaccine 29:334-343.
103. Duintjer Tebbens, R. J., M. A. Pallansch, O. M. Kew, et al. 2006a. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis 26(6):1471-1505.
104. Duintjer Tebbens, R. J., M. A. Pallansch, O. M. Kew, et al. 2005. A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. Am. J. Epidemiol. 162(4):358-372.
105. Duintjer Tebbens, R. J., M. A. Pallansch, O. M. Kew, et al. 2008. Uncertainty and sensitivity analyses of a decision analytic model for post-eradication polio risk management. Risk Analysis 28(4):855-876.
106. Duintjer Tebbens, R. J., N. Sangrujee, and K. M. Thompson. 2006b. The costs of polio risk management policies after eradication. Risk Analysis 26(6):1507-1531.
107. Duintjer Tebbens, R. J., and K. M. Thompson. 2009. Priority shifting and the dynamics of managing eradicable infectious diseases. Manag. Sci. 55(4):650-663.
108. Duke, B. O. L., and J. Anderson. 1972. A comparaison of the lesions produced in the corna of the rabbit eye by microfi laria of the forest and Sudan-Savannah strains of Onchocerca volvulus from Cameroon. Tropenmed. Parasitol. 23:354-368.
109. Duke, B. O. L., and A. Garner. 1976. Fundus lesions in the rabbit eye following inoculation of Onchocerca volvulus in the posterior segment. Tropenmed. Parasitol. 27:3-17.
110. Dye, C., and B. G. Williams. 2008. Eliminating human tuberculosis in the twenty-fi rst century. J. R. Soc. Interface 5(23):653-662.
111. Edmunds, W. J., G. F. Medley, and D. J. Nokes. 1999. Evaluating the cost-effectiveness of vaccination programmes: A dynamic perspective. Stat. Med. 18(23):3263-3282.
112. Eisenhardt, K., J. Kahwajy, and L. J. Bourgeois, III. 1997. How Teams Have a Good Fight. Boston: Harvard Business Review.
113. Ekman, G., I. Pathmanathan, and J. Liljestrand. 2008. Alma-Ata: Rebirth and Revision 7. Integrating health interventions for women, newborn babies, and children: A framework for action. Lancet 372:990-1000.
114. El-Sayed, N., Y. El-Gamel, A. A. Abbassy, et al. 2008. Monovalent type 1 oral poliovirus vaccine in newborns. N. Engl. J. Med. 359(16):1655-1665.
115. Emerson, C., and P. Singer. 2010. Is there an ethical obligation to complete polio eradication? Lancet 375:1340-1341.
116. Faden, R., and S. Shebaya. 2010. Public health ethics. In: The Stanford Encyclopedia of Philosophy (summer 2010 edition). http://plato.stanford.edu/archives/sum2010/ entries/publichealth-ethics/ (accessed 8 April 2011).
117. Fahey, L., W. R. King, and V. K. Narayanan. 1981. Environmental scanning and forecasting in strategic planning: The state of the art. Long Range Plann. 14(1):32- 39.
118. Farchy, D. J. 2005. A common good: Whither the global eradication of the measles virus? SSRN eLibrary. http://ssrn.com/paper=714302 (accessed 20 June 2010).
119. Feilden, R., and O. F. Nielsen. 2001. Immunization and Health Reform: Making Reforms Work for Immunization. A Reference Guide. WHO/V&B/01.44. Geneva: WHO.
120. Feinberg, J. 1984. The Moral Limits of the Criminal Law: Harm to Others. vol. 1. New York: Oxford Univ. Press.
121. Fenner, F., A. J. Hall, and W. R. Dowdle. 1998. What is eradication? In: The Eradication of Infectious Diseases, ed. W. R. Dowdle and D. R. Hopkins, pp. 3-17. Dahlem Workshop Report, J. Lupp, series ed. Chichester: John Wiley & Sons.
122. Fenner, F., D. A. Henderson, I. Arita, Z. Jezek, and I. D. Ladnyi. 1988. Smallpox and Its Eradication. Geneva: WHO.
123. Ferroni, M., and A. Modi, eds. 2002. International Public Goods: Incentives, Measurement, and Financing. Amsterdam: Kluwer.
124. Fine, P. E., and J. A. Clarkson. 1986. Individual versus public priorities in the determination of optimal vaccination policies. Am. J. Epidemiol. 124(6):1012- 1020.
125. Fine, P. E., and U. K. Griffiths. 2007. Global poliomyelitis eradication: Status and implications. Lancet 370:132-133.
126. Foege, W. H. 1971. Measles vaccination in Africa. In: Proc. of the Intl. Conf. on the Application of Vaccines against Viral, Rickettsial, and Bacterial Diseases of Man, pp. 207-212. Washington, D.C.: Pan American Health Organization.
127. Foege, W. H. 1998. Thoughts on organization for disease eradication. In: The Eradication of Infectious Diseases, ed. W. R. Dowdle and D. R. Hopkins, pp. 187-191. Dahlem Workshop Reports, J. Lupp, series ed. Chichester: John Wiley & Sons.
128. Frenk, J. 2006. Bridging the divide: Comprehensive reform to improve health in Mexico. WHO Commission on Social Determinants of Health, Nairobi, Kenya. http://www. who.int/social_determinants/resources/frenk.pdf (accessed 8 November 2010).
129. Fulton, B. D., R. M. Scheffler, S. P. Sparkes, et al. 2011 Health workforce skill mix and task shifting in low income countries: A review of recent evidence. Human Res. Health 19(1):1.
130. Gainotti, S., N. Moran, C. Petrini, and D. Shickle. 2008. Ethical models underpinning responses to threats to public health: A comparison of approaches to communicable disease control in Europe. Bioethics 22(9):466-476.
131. Galindo, M. A., M. Santin, S. Resik, et al. 1998. The elimination of measles from Cuba. Pan. Am. J. Public Health 4:171-177.
132. Gambhir, M., M. Bockarie, D. Tisch, et al. 2010. Geographic and ecologic heterogeneity in elimination thresholds for the major vector-borne helminthic disease, lymphatic filariasis. BMC Biology 8(1):22.
133. GAO. 2004. Emerging infectious diseases: Asian SARS outbreak challenged international and national responses. Report to the Chairman, Subcommittee on Asia and the Pacifi c, Committee on International Relations, House of Representatives. GAO-04-564. Washington, D.C.: GAO.
134. Garrett, L. 2007. The challenge of global health. Foreign Affairs 86(1):14-38.
135. Gauri, V., and P. Khaleghian. 2002. Immunization in developing countries: Its political and organizational determinants. World Development 30(12):2109-2132.
136. GAVI Alliance. 2004. Guidelines for Preparing Proposals for GAVI/Vaccine Fund Investment (second draft, version 4). http://www.gavialliance.org/resources/13th_ brd_Investment_case_guidelines_2.pdf (accessed 8 April 2011).
137. GAVI Alliance. 2006. Rotavirus and pneumococcal investment cases, notes from 29 November 2006 meeting, Doc A.1. http://www.gavialliance.org/resources/Rotavirus_Pneumo_ Investment_Case_for_board_Nov06.pdf. (accessed 17 October 2010).
138. GAVI Alliance. 2010a. Approved support. http://www.gavialliance.org/performance/ commitments/index.php (accessed 21 October 2010).
139. GAVI Alliance. 2010b. Goals. http://www.gavialliance.org/vision/strategy/goals/index.php (accessed 7 June 2010).
140. GAVI Alliance. 2010c. International fi nance facility for immunisation. http://www.iffimmunisation. org/ (accessed 17 October 2010).
141. Geoffard, P. Y., and T. Philipson. 1997. Disease eradication private versus public vaccination. Am. Econ. Rev. 87(1):222-230.
142. Gerencser, M., R. Van Lee, F. Napolitano, and C. Kelly. 2008. Megacommunities: How Leaders of Government, Business and Nonprofi ts Can Tackle Today's Global Challenges Together. New York: St. Martin's Press.
143. Gersovitz, M., and J. S. Hammer. 2003. Infectious diseases, public policy, and the marriage of economics and epidemiology. World Bank Research Observer 18(2):129-157.
144. GFATM. 2010. About the global fund. http://www.theglobalfund.org/en/about/?lang=en (accessed 25 May 2010).
145. GIVS. 2011. Global immunization vision and strategy. http://www.who.int/ immunization/givs/en/index.html (accessed 6 February 2011).
146. Global Polio Eradication Initiative. 2010. Global Polio Eradication Initiative Strategic Plan 2010-2012. Geneva: WHO.
147. Gold, M. R., J. E. Siegel, L. B. Russel, and M. C. Weinstein. 1996. Cost-effectiveness in Health and Medicine. New York: Oxford Univ. Press.
148. Golding, M. 1972. Obligations to Future Generations. The Monist 56:85.
149. Goleman, D. 1995. Emotional Intelligence. New York: Bantam Books.
150. Goleman, D. 2000. Leadership that gets results. Product no. 4487. Harvard Bus. Rev. 78(3):1-13.
151. Gonzalez, C. L. 1965. Mass Campaigns and General Health Services, Public Health papers, No. 29. Geneva: WHO.
152. Goodman, R. A., K. L. Foster, F. L. Trowbridge, and J. P. Figueroa. 1998a. Global disease elimination and eradication as public health strategies. Bull. WHO 76(2):1- 162.
153. Goodman, R. A., D. R. Hopkins, I. Arita, et al. 1998b. When and how should eradication programs be implemented? In: The Eradication of Infectious Diseases, ed. W. R. Dowdle and D. R. Hopkins, pp. 193-205. Dahlem Workshop Reports, J. Lupp, series ed. Chichester: John Wiley & Sons.
154. Grassly, N. C., C. Fraser, J. Wenger, et al. 2006. New strategies for the elimination of polio from India. Science 314:1150-1153.
155. Gravelle, H., and D. Smith. 2001. Discounting for health effects in cost-benefi t and cost-effectiveness analysis. Health Econ. 10(7):587-599.
156. Greenough, P. 1995. Intimidation, coercion and resistance in the final stages of the South Asian Smallpox Eradication Campaign, 1973-1975. Soc. Sci. Med. 41(5):633-645.
157. Griffiths, U. K., P. Hanvoravongchai, V. Oliveira-Cruz, S. Mounier-Jack, and D. Balabanova. 2010. A toolkit for assessing the impacts of measles eradication activities on immunization services and health systems at country level: Developed for a multi-country study undertaken between July 2009-July 2010. http://www. cdprg.org/admin/editor_files/downloads/Measles_and_health_systems_toolkit.pdf (accessed 28 January 2011).
158. Gupta, A. G., C. A. Moyera, and D. T. Stern. 2005. The economic impact of quarantine: SARS in Toronto as a case study. J. Infect. 50:386-393.
159. Gyapong, J., M. Gyapong, N. Yellu, et al. 2010. Integration of control of neglected tropical diseases into health-care systems: Challenges and opportunities. Lancet 375(9709):160-165.
160. Gyapong, J., and N. A. Twum-Danso. 2006 Editorial: Global elimination of lymphatic filariasis: fact or fantasy? Trop. Med. Intl. Health 11(2):125-128.
161. Haddad, D., C. Cross, B. Thylefors, et al. 2008. Health care at the end of the road: Opportunities from 20 years of partnership in onchocerciasis control. Global Public Health 3(2):187-196.
162. Hall, B. F., and Anthony S. Fauci. 2009. Malaria control, elimination, and eradication: The role of the evolving biomedical research agenda. J. Infect. Dis. 200(11):1639- 1643.
163. Hart, H. L. A. 1994. The Concept of Law. Oxford: Clarendon Press.
164. Hawkins, J. 2006. Justice and placebo controls. Soc. Theory Prac. 32(3):468.
165. Hawkins, J., and E. J. Emanuel, eds. 2008. Exploitation and Developing Countries: The Ethics of Clinical Research. Princeton: Princeton Univ. Press.
166. Hecht, R., and R. Shah. 2006. Recent trends and innovations in development assistance for health. In: Disease Control Priorities in Developing Countries (2nd edition), ed. D. T. Jamison et al. Washington, D.C.: World Bank.
167. Henderson, D. A. 1987. Principles and lessons from the smallpox eradication programme. Bull. WHO 65:535-46.
168. Henderson, D. A. 1998. Eradication: Lessons from the past. Bull. WHO 76(Suppl. 2):17-21.
169. Hinman, A. R. 1984. Prospects for disease eradication or elimination. NY State J. Med. 84(10):502-506.
170. Hinman, A. R., and D. R. Hopkins. 1998. Lessons from previous eradication programs. In: The Eradication of Infectious Diseases, ed. W. R. Dowdle and D. R. Hopkins, pp. 19-31. Dahlem Workshop Report, J. Lupp, series ed. Chichester: John Wiley & Sons.
171. Hissette, J. 1932. Mémoire on Onchocerca volvulus and ocular manifestations in the Belgian Congo. Ann. Soc. Belge. Méd. Trop. 12:433-529.
172. Homeida, M., E. Braide, E. Elhassan, et al. 2002. APOC's strategy of communitydirected treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. Ann. Trop. Med. Parasitol. 96(1):93-104.
173. Hopkins, A. D. 2009. Challenges for the integration of mass drug administrations against multiple neglected tropical diseases. Ann. Trop. Med. Parasitol. 103(1):S23- S31.
174. Hopkins, D. R. 2009. The allure of eradication. Global Health Magazine, http://www. globalhealthmagazine.com/top_stories/the_allure_of_eradication (accessed 11 October 2010).
175. Horton, R. 2009. Venice statement: Global health initiatives and health systems. Lancet 374:10-12.
176. Howie, S. R. C., M. Antonio, A. Akisanya, et al. 2007. Re-emergence of Haemophilus infl uenzae type b (Hib) disease in The Gambia following successful elimination with conjugate Hib vaccine Vaccine 25(34):6305-6309.
177. Hughes, J., and J. Weiss. 2007. Simple rules for making alliances work. Harvard Bus. Rev. 85(11):122-126.
178. Hull, H. F. 2007. Pax polio. Science 275:40-41.
179. Hunt, T. 1937. Co-opetition. Los Angeles Times, Nov. 20, 1937, p. a4.
180. Huppatz, C., C. Capuano, K. Palmer, P. Kelly, and D. Durrheim. 2009. Lessons from the Pacifi c programme to eliminate lymphatic fi lariasis: A case study of 5 countries. BMC Infectious Diseases 9(1):92.
181. Hutubessy, R., D. Chisholm, T. Edejer, and WHO-CHOICE. 2003. Generalized costeffectiveness analysis for national-level priority-setting in the health sector. Cost Effect. Resource Allocation 1(1):8.
182. Ibarra, H., and J. Suesse. 1997. Building coalitions. Product no. 497055. Harvard Bus. Rev. 75(1):1-8.
183. Igneski, V. 2006. Perfect and imperfect duties to aid. Soc. Theory Prac. 32(3):439-466.
184. IHP+. International Health Partnership 2007. Available from http://www. internationalhealthpartnership.net/en/documents/category/offi cial_ihp_documents. (accessed 1 December 2010).
185. IHP+. International Health Partnership. 2009. Taskforce on Innovative International Financing for Health Systems: More money for health, and more health for the money. www. internationalhealthpartnership.net//CMS_fi les/documents/taskforce_report_EN.pdf (accessed 1 December 2010).
186. IHP+. International Health Partnership. 2010. Welcome to the International Health Partnership and related initiatives. http://www.internationalhealthpartnership.net/en/home (accessed 7 June 2010).
187. IMF. 2010. IMF Survey Magazine interview: IMF moves on gold sales, SDR trading. 17 February 2010. http://www.imf.org/external/pubs/ft/survey/so/2010/int021710c. htm (accessed 16 October 2010).
188. ITFDE. 2008. Updated table of diseases considered as candidates for global eradication by the International Task Force for disease eradication. http://www.cartercenter.org/ resources/pdfs/news/health_publications/itfde/updated_disease_candidate_table. pdf (accessed 16 October 2010).
189. ITI. 2010. Zithromax in the elimination of blinding trachoma: A program manager's guide. International Trachoma Initiative. http://www.trachoma.org/documents/ ITIZithromaxManagersGuide_en_000.pdf (accessed 23 October 2010).
190. Jamison, D. T., and J. S. Jamison. 2003. Discounting: Disease Control Priority Project Working Paper. Fogarty International Center: National Institute of Health
191. Janis, I. L. 1982. Groupthink: Psychological Studies of Policy Decisions and Fiascoes, 2nd ed. New York: Houghton Miffl in.
192. Jegede, A. S. 2007. What led to the Nigerian boycott of the polio vaccination campaign? PLoS Med. 4(3):e73.
193. Jenner, W. 1801. The Origin of the Vaccine Inoculation. London: D. M. Shury. (Available at http://pyramid.spd.louisville.edu/~eri/fos/jenner_Origin.pdf, accessed 1 July 2010).
194. Jonas, H. 1984. The Imperative of Responsibility: In Search of an Ethics for the Technological Age. Chicago: Univ. Chicago Press.
195. Jones, G., R. W. Steketee, R. E. Black, Z. A. Bhutta, and S. S. Morris. 2003. Bellagio Child Survival Study Group. How many child deaths can we prevent this year? Lancet 362:65-71.
196. Kabatereine, N. B., M. N. Malecela, M. Lado, et al. 2010. How to (or not to) integrate vertical programmes for the control of major neglected tropical diseases in sub-Saharan Africa. PLoS Negl. Trop. Dis. 4(6):e755.
197. Kabayo, J. P. 2002. Aiming to eliminate tsetse from Africa. Trends Parasitol. 18(11):473-475.
198. Kant, I. 1785/1993. Grounding for the Metaphysics of Morals (trans. by J. W. Ellington). Indianapolis: Hackett Publ.
199. Kanter, R. M. 1979. Power failure in management circuits. Harvard Bus. Rev. 57(7):65- 76.
200. Kates, J. 2010. Policy Brief, April 2010. The U.S. global health initiative: Key issues. http://www.kff.org/globalhealth/8063.cfm (accessed 2 July 2010).
201. Kaufmann, J. R., and H. Feldbaum. 2009. Diplomacy and the polio immunization boycott in northern Nigeria. Health Affairs 28(4):1091.
202. Keegan, R. A., A. Dabbagh, P. M. Strebel, and S. L. Cochi. 2011. Comparing measles with previous eradication programs: Enabling and constraining factors. J. Infect. Dis., in press.
203. Kelly, C., M. Gerencser, F. Napolitano, and R. Van Lee. 2007. The defi ning features of a megacommunity. Strategy + Business (June 12), http://www.strategy-business.com/ article/li00029?pg=0 (accessed 2 February 2011).
204. Kew, O. M., R. W. Sutter, E. M. de Gourville, W. R. Dowdle, and M. A. Pallansch. 2005. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 59:587-635.
205. Khan, M. M., and J. Ehreth. 2003. Costs and benefits of polio eradication: A long-run global perspective. Vaccine 21(7-8):702-705.
206. Kirigia, J. M., and S. P. Barry. 2008. Health challenges in Africa and the way forward. Intl. Arch. Med. 18(1):27.
207. Kotter, J. P. 2001. What leaders really do. Harvard Bus. Rev. 79(12):3-11.
208. Kumar, A. 1990. Operational research need in guineaworm eradication programme. J. Commun. Dis. 22(4):236-242.
209. Lahariya, C. 2007. Global eradication of polio: The case for "finishing the job." Bull. WHO 85(6):487-492.
210. Lavery, J. V., P. O. Tinadana, T. W. Scott, et al. 2010. Towards a framework for community engagement in global health research. Trends Parasitol. 26:279-283.
211. Lawn, J. E., J. Rohde, S. Rifkin, et al. 2008. Alma-Ata: Rebirth and Revision 1. Alma-Ata 30 years on: Revolutionary, relevant, and time to revitalize. Lancet 372:917- 927.
212. Lazcano-Ponce, E., B. Allen, and C. C. González. 2005. The contribution of international agencies to the control of communicable diseases. Arch. Med. Res. 36(6):731-738.
213. Lee, J. W., B. Melgaard, H. F. Hull, D. Barakamfitiye, and J. M. Okwo-Bele. 1998. Ethical dilemmas in polio eradication. Am. J. Public Health 88:130-132.
214. Lemon, S. M., and S. E. Robertson. 1991. Global eradication of poliomyelitis: Recent progress, future prospects, and new research priorities. Prog. Med. Virol. 38:42-45.
215. Leyton-Brown, K., and Y. Shoham. 2008. Essentials of Game Theory: A Concise, Multidisciplinary Introduction. San Rafael, CA: Morgan & Claypool.
216. Lockwood, D. N., and S. Suneetha. 2005. Leprosy: Too complex a disease for a simple elimination paradigm. Bull. WHO 83:230-235.
217. Loevinsohn, B., B. Aylward, R. Steinglass, et al. 2002. Impact of targeted programs on health systems: A case study of the polio eradication initiative. Am. J. Public Health 92(1):1923.
218. Lu, C., M. Schneider, P. Gubbins, et al. 2010. Public fi nancing of health in developing countries: A cross-national systematic analysis. Lancet 375(9723):1375-1387.
219. Malaria Elimination Group. 2011. http://www.malariaeliminationgroup.org/about (accessed 8 April 2011).
220. Malaria Eradication Research Agenda. 2011. http://malera.tropika.net/ (accessed 8 April 2011).
221. Malecela, M., W. Lazarus, U. Mwingira, et al. 2009. Eliminating LF: A Progress Report from Tanzania. J. Lymphoedema 4(1):10-12.
222. Marais, B. J., and M. Pai. 2007. Recent advances in the diagnosis of childhood tuberculosis. Arch. Dis. Child. 92:446-452.
223. March, J. G., and H. A. Simon. 1958. Organizations. New York: John Wiley & Sons.
224. Más Lago, P. 1999. Eradication of poliomyelitis in Cuba: A historical perspective. Bull. WHO 77(8):681-687.
225. McCoy, D., S. Chand, and D. Sridhar. 2009. Global health funding: How much, where it comes from and where it goes. Health Policy Plan. 24(6):407-417.
226. McCurry, J. 2008. G8 meeting disappoints on global health. Lancet 372(9634):191- 194.
227. McKinsey. 2010. The McKinsey 7S framework. http://www.mindtools.com/pages/ article/newSTR_91.htm (accessed 13 October 2010).
228. Mectizan Donation Program. 2010. History. http://www.mectizan.org/history (accessed 25 May 2010).
229. Melgaard, B., A. Creese, B. Aylward, et al. 1998. Disease eradication and health systems development. Bull. WHO 76(2):26-31.
230. Merritt, M. 2007. Bioethics, philosophy, and global health. Yale J. Health Policy, Law & Ethics 7(2):273-317.
231. Michael, E., M. N. Malecela, M. Zervos, and J. W. Kazura. 2008. Global eradication of lymphatic fi lariasis: the value of chronic disease control in parasite elimination programmes. PLoS One 13(3):e2936.
232. Miles, S. A., and M. D. Watkins. 2007. The leadership team: Complementary strengths or confl icting agendas? Harvard Bus. Rev., www.heidrick.com/PublicationsReports/ Documents/HBR_LeadershipTeam.pdf (accessed 7 September 2010).
233. Miller, M. A., S. Barrett, and D. A. Henderson. 2006. Control and eradication. In: Disease Control Priorities in Developing Countries, ed. D. Jamison et al., pp. 1163- 1176. New York: World Bank and Oxford Univ. Press.
234. Mills, A. 1983. Vertical vs horizontal health programmes in Africa: Idealism, pragmatism, resources and effi ciency. Soc. Sci. Med. 17(24):1971-1981.
235. Mills, A. 2005. Mass campaigns versus general health services: What have we learnt in 40 years about vertical versus horizontal approaches? Bull. WHO 83(4):315-316.
236. Ministry of Health of Viet Nam. 2006. Multi-year plan for EPI: 2006-2010. http:// www.gavialliance.org/resources/Vietnam_cMYP_2006_10.pdf (accessed 23 January 2010).
237. MMWR. 1993. Recommendations of the International Task Force for Disease Eradication. MMWR 42(RR-16):1-38.
238. Møgedal, S., and B. Stenson. 2000. Disease Eradication: Friend or Foe to the Health System? Synthesis report from fi eld studies on the polio eradication initiative in Tanzania, Nepal and the Lao People's Democratic Republic. Geneva: WHO, Dept. of Vaccines and Biologicals.
239. Mohamed, A. J., P. Ndumbe, A. J. Hall, et al. 2009. Independent evaluation of major barriers to interrupting poliovirus transmission. Executive summary. http://www. polioeradication.org/content/general/Polio_Evaluation_CON.pdf (accessed 28 January 2011).
240. Molyneux, D. H. 2009. 10 years of success in addressing lymphatic fi lariasiss. Lancet 373(9663):529-530.
241. Molyneux, D. H., D. R. Hopkins, and N. Zagaria. 2004. Disease eradication, elimination and control: The need for accurate and consistent usage. Trends Parasitol. 20:347- 351.
242. Moore, G. E. 1903. Principia Ethica. Cambridge: Cambridge Univ. Press.
243. MPR News. 2009. Give MN: A look at the numbers http://minnesota.publicradio.org (accessed 7 September 2010).
244. Narain, J. P., A. P. Dash, and B. Parnell. 2010. Elimination of neglected tropical diseases in the south-east Asia region of the World Health Organization. Bull. WHO 88:206-210.
245. Needham, C. A., and R. Canning. 2003. Global Disease Eradication: The Race for the Last Child. Washington, D.C.: ASM Press.
246. Ngoumou, P., and J. F. Wash. 1993. A manuel for rapid epidemiological mapping of onchocerciasis. Document No. TDR/TDE/ONCHO/93.4. Geneva: WHO.
247. NIAID and NIH. 2008a. NIAID malaria working group: NIAID research agenda for malaria. http://www.niaid.nih.gov/topics/malaria/documents/researchagenda.pdf (accessed 4 November 2010).
248. NIAID and NIH. 2008b. NIAID strategic plan for malaria research: Efforts to accelerate control and eradication of malaria through biomedical research. http://www.niaid.nih.gov/ topics/malaria/documents/strategicplan.pdf (accessed 4 November 2010).
249. Nohria, N., W. Joyce, and B. Roberson. 2003. What really works. Harvard Bus. Rev. July:42-52.
250. Obadairo, C. 2010. Feasibility of measles eradication: stakeholder analysis. Global Technical Consultation Meeting on the Feasibility of Measles Eradication, July 28-30, 2010, at Washington, D.C., Washington, D.C.: PAHO.
251. Obadare, E. 2005. A crisis of trust: History, politics, religion and the polio controversy in northern Nigeria. Patt. Prejudice 39(3):265.
252. OECD. 1998. Effects of European Union accession, Part 1: Budgeting and fi nancial control, SIGMA Paper No. 19, Appendix 3: List of Useful Terms. http://ideas.repec. org/p/oec/govaac/19-en.html (accessed 17 October 2010).
253. OECD. 2005. Paris Declaration on aid effectiveness. http://www.oecd.org/ dataoecd/11/41/34428351.pdf (accessed 17 October 2010).
254. OECD. 2008a. The Paris Declaration and Accra Agenda for Action: Full related documentation. http://www.oecd.org/dataoecd/11/41/34428351.pdf (accessed 25 May 2010).
255. OECD. 2008b. Survey on monitoring the Paris Declaration: Making aid more effective by 2010. http://www.oecd.org/document/0/0,3343, en_2649_3236398_41203264_1_1_1_1,00.html (accessed 22 November 2010).
256. Oliveira-Cruz, V., C. Kurowski, and A. Mills. 2003. Delivery of priority health services: Searching for synergies within the vertical versus horizontal debate. J. Intl. Develop. 15:67-86.
257. Oliveira Cruz, V., and B. McPake. 2010. The "aid contract" and its compensation scheme: A case study of the performance of the Ugandan health sector. Soc. Sci. Med. 71(7):1357-1365.
258. O'Neil, J. 1875. On the presence of fi laria in craw-craw. Lancet 1:265-266.
259. O'Neill, O. 2002. Autonomy and Trust in Bioethics. Cambridge: Cambridge Univ. Press.
260. O'Neill, O. 2005. The dark side of human rights. Intl. Affairs 81:427-439.
261. Oomman, N., M. Bernstein, and S. Rosenzweig. 2007. Following the Funding for HIV/ AIDS: A Comparative Analysis of the Funding Practices of PEPFAR, the Global Fund and World Bank MAP in Mozambique, Uganda and Zambia. Washington, D.C.: Center for Global Development.
262. Ooms, G., K. Decoster, K. Miti, et al. 2010. Crowding out: Are relations between international health aid and government health funding too complex to be captured in averages only? Lancet 375(9723):1403-1405.
263. Ottesen, E. A., W. R. Dowdle, F. Fenner, et al. 1998. How is eradication to be defi ned and what are the biological criteria? In: The Eradication of Infectious Diseases, ed. W. R. Dowdle and D. R. Hopkins, pp. 47-59. Dahlem Workshop Report, J. Lupp, series ed. Chichester: John Wiley & Sons.
264. Ottesen, E. A., P. J. Hooper, M. Bradley, and G. Biswas. 2008. The global programme to eliminate lymphatic fi lariasis: Health impact after 8 years. PLoS Negl. Trop. Dis. 2(10):e317.
265. Oxfam. 2002. False hope or new start? The global fund to fi ght HIV/AIDS, TB, and Malaria. http://www.oxfam.org.uk/resources/policy/health/downloads/bp24_ globalfund.pdf (accessed 8 April 2011).
266. PAHO. 2003. 44th Direction Council. Resolution CD44.R1. Sustaining immunization programs: Elimination of rubella and congenital rubella syndrome. http://www. paho.org/English/gov/cd/cd44-r1-e.pdf (accessed 27 January 2011).
267. PAHO. 2004. XVI Meeting: Final report of the technical advisory group on vaccinepreventable diseases, Mexico City, Nov. 3-5, pp. 1-55. http://www.paho.org/ English/AD/FCH/IM/TAG16_2004_FinalReport_Eng.pdf (accessed 27 January 2011).
268. Panda, A., and R. K. Gupta. 2001. Understanding organizational culture: A perspective on roles for leaders. Vikalpa 26(4):1-19.
269. Parsonage, M., and H. Neuburger. 1992. Discounting and health benefi ts. Health Econ. 1(1):71-76.
270. Patel, P., B. Roberts, L. Conteh, S. Guy, and L. Lee-Jones. 2010. A review of global mechanisms for tracking offi cial development assistance for health in countries affected by armed confl ict. Health Policy, doi:10.1016/j.healthpol.2010.08.007.
271. PATH's Rotavirus Vaccine Program. 2006. Accelerating the Introduction of Rotavirus Vaccines into GAVI-Eligible Countries. http://www.gavialliance.org/resources/ Rotavirus_Investment_Case_Oct06.pdf (accessed 8 April 2011).
272. Paul, Y. 2005. Polio eradication programme: Some ethical issues. Indian J. Med. Ethics 2(4):115.
273. Paul, Y., and A. Dawson. 2005. Some ethical issues arising from polio eradication programmes in India. Bioethics 19(4):393.
274. Pearson, M., B. Kent, and P. Sok. 2008. Global health partnerships: Deploying vertical fi nancing to support horizontal efforts. DFID Health Resource Centre. http:// network.human-scale.net/docs/DOC-1257 (accessed 27 January 2011).
275. Perera, M., M. Whitehead, and D. H. Molyneaux. 2007. Neglected patients with a neglected disease? A qualitative study of lymphatic fi lariasis. PLoS Negl. Trop. Dis. 1:e128.
276. Piva, P., and R. Dodd. 2009. Where did all the aid go? An in-depth analysis of increased health aid flows over the past 10 years. Bull. WHO 87(12):930-939.
277. Polio Eradication Initiative. 2010a. Financial resource requirements. http://www. polioeradication.org/fundingbackground.asp (accessed 25 May 2010).
278. Polio Eradication Initiative. 2010b. Strategic plan 2010-2012. http://www.polioeradication.org/Portals/0/ Document/StrategicPlan/StratPlan2010_2012_ENG.pdf (accessed 6 February 2011).
279. Pope, C., and N. Mays, eds. 1996. Qualitative Research in Health Care. London: BMJ Publishing Group.
280. Powers, M., and R. Faden. 2006. Social Justice: the Moral Foundations of Public Health and Health Policy. Oxford: Oxford Univ. Press.
281. Rajaratnam, J. K., J. R. Marcus, A. D. Flaxman, et al. 2010. Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970-2010: A systematic analysis of progress towards Millenium Development Goal 4. Lancet 375:1988- 2008.
282. Ravishankar, N., P. Gubbins, R. J. Cooley, et al. 2009. Financing of global health: Tracking development assistance for health from 1990 to 2007. Lancet 373:2113- 2124.
283. Renne, E. 2006. Perspectives on polio and immunization in Northern Nigeria. Soc. Sci. Med. 63:1857-1869.
284. Ridley, H. 1945. Ocular Onchocerciasis, including an investigation in the Gold Coast. Br. J. Ophthalmol. 10(Suppl):1-58.
285. Rifkin, S. B., and G. Walt. 1986. Why health improves: Defi ning the issues concerning comprehensive primary health care and selective primary health care. Soc. Sci. Med. 23(6):559-566.
286. Ritchie, J., and L. Spencer. 1994. Qualitative data analysis for applied policy research. In: Analyzing Qualitative Data, ed. B. A. Burgess, pp. 173-194. London: Routledge.
287. Robels, R. 1917. Enfermedad nueva in Guatemala. Juventud Med. 17:97-115.
288. Roberts, J. 2004. Alliances, Coalitions and Partnerships. Gabriola Island, BC: New Society Publ.
289. Roberts, J., E. Neumann, C. W. Guckel, and R. B. Highton. 1986. Onchocerciasis in Kenya 9, 11, and 18 years after elimination of the vector. Bull. WHO 64:667-681.
290. Rockefeller Foundation. 2003. Human resources: A joint learning initiative. http://www. rockefellerfoundation.org/uploads/fi les/ad7cea0d-33f9-4de3-82c1-dabd88f5ca4f-03hrh.pdf (accessed 23 November 2010).
291. Rogers, D. J., and S. E. Randolph. 2002. A response to the aim of eradicating tsetse from Africa. Trends Parasitol. 18:534-536.
292. Rogers, E. M. 2003. Diffusion of Innovations, 5th edition. New York: Free Press.
293. Ropero-Alvarez, A. M., H. J. Kurtis, M. C. Danovaro-Holliday, C. Ruiz Matus, and J. K. Andrus. 2009. Expansion of seasonal infl uenza vaccination in the Americas. BMC Public Health 9:361.
294. Rosenstein, S., and L. Garrett. 2006. Olio's Return, a WHO-Done it? The American Interest 1(3):19-27.
295. Rowden, R. 2010. Why health advocates must get involved in development economics: The case of the International Monetary Fund. Intl. J. Health Serv. 40(1):183-187.
296. Ryman, T. K., V. Dietz, and K. L. Cairns. 2008. Too little but not too late: Results of a literature review to improve routine immunization programs in developing countries. BMC Health Serv. Res. 8:134.
297. Salisbury, D. 1998. Report of the workgroup on disease elimination/eradication and sustainable health development. Bull. WHO 76(2):72-79.
298. Samba, E. M. 1994. The Onchocerciasis Control Program in West Africa: An Example of Effective Public Health Management. Geneva: WHO.
299. Sangrujee, N., R. J. Duintjer Tebbens, V. M. Cáceres, and K. M. Thompson. 2003. Policy decision options during the fi rst 5 years following certifi cation of polio eradication. Medscape Gen. Med. 5(4):35.
300. Sathyamala, C., M. Onkar, R. Dasgupta, and R. Priya. 2005. Polio eradication initiative in India: Deconstructing the GPEI. Intl. J. Health Serv. 35(2):361-383.
301. Sauerbrey, M. 2008. The onchocerciasis elimination program for the Americas. Ann. Trop. Med. Parasitol. 102(1):S25-S29.
302. Schieber, G., C. Baeza, D. Kress, and M. Maier. 2006. Financing health systems in the 21st century. In: Disease Control Priorities in Developing Countries (2nd edition), ed. D. T. Jamison et al. Washington, D.C.: World Bank.
303. Schmunis, G. A., F. Zicker, and A. Moncayo. 1996. Interruption of Chagas' disease transmission through vector elimination. Lancet 348:1171.
304. Schwarz, E. C., J. Renk, A. D. Hopkins, R. Huss, and A. Foster. 1999. A method to determine the coverage of ivermectin distribution programs in onchocerciasis control Ann. Trop. Med. Parasitol. 92(7):793-796.
305. Shiffman, J. 2006. Donor funding priorities for communicable disease control in the developing world. Health Policy Plan. 21(6):411-420.
306. Shigayeva, A., R. Atun, M. McKee, and R. Coker. 2010. Health systems, communicable diseases and integration. Health Policy Plan. 25(Suppl. 1):i4-i20.
307. Shulman, S. T. 2004. The history of pediatric infectious diseases. Pediatric Res. 55:163-176.
308. Singer, P. 1997. The drowning child and the expanding circle. New Internationalist, http://www.newint.org/features/1997/04/05/drowning/ (accessed 8 April 2011).
309. Sinha, K. 2008. Study fi nds polio drive counter-productive. The Times of India, http://timesofi ndia.indiatimes.com/Study_fi nds_polio_drive_counter-productive/ rssarticleshow/3089610.cms (accessed 1 June 2008).
310. Slonim, D., E. Svandova, P. Strand, and C. Benes. 1995. History of poliomyelitis in the Czech Republic. Part III. Cen. Europ. J. Public Health 3(3):124-126.
311. Smith, C. E. 1964. Factors in the transmission of virus infections from animals to man. Sci. Basis Med. Annu. Rev.:125-150.
312. Smith, R. D., R. Beaglehole, D. Woodward, and N. Drager, eds. 2003. Global Public Goods for Health: Health Economic and Public Health Perspectives. Oxford: Oxford Univ. Press.
313. Smith, R. D., D. Woodward, A. Acharya, R. Beaglehole, and N. Drager. 2004. Communicable disease control: A "Global Public Good" perspective. Health Policy Plan. 19(5):271-278.
314. Surber, J. P. 1977. Obligations to future generations: Explorations and problemata. J. Value Inquiry 11(2):107.
315. Sutter, R. W., and S. L. Cochi. 1997. Comment: Ethical dilemmas in worldwide polio eradication programs. Am. J. Public Health 87(6):913-915.
316. Sutter, R. W., T. J. John, H. Jain, et al. 2010. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: A randomised, double-blind, controlled trial. Lancet 376:1682-1688.
317. Tambini, G., J. K. Andrus, J. W. Fitzsimmons, and M. R. Periago. 2006. Regional immunization programs as a model for strengthening cooperation among nations. Pan. Am. J. Public Health 20(1):54-59.
318. Tangcharoensathien, V., and W. Patcharanarumol. 2010. Global health initiatives: Opportunities or challenges? Health Policy Plan. 25:101-103.
319. Tangermann, R. H., H. F. Hull, B. Nkowane, H. Everts, and R. B. Aylward. 2000. Eradication of poliomyelitis in countries affected by confl ict. Bull. WHO 78:330- 338.
320. Taylor, C., H. Cordeiro, and F. Cutts. 1995. Taylor Commission. The Impact of the Expanded Program on Immunization and the Polio Eradication Initiative on Health Systems in the Americas. Washington, D.C.: PAHO.
321. Taylor, C., F. Cutts, and M. Taylor. 1997. Ethical dilemmas in current planning for polio eradication. Am. J. Public Health 87(6):922-925.
322. Taylor, C., and R. J. Waldman. 1998. Designing eradication programs to strengthen primary health care. In: The Eradication of Infectious Diseases, ed. W. R. Dowdle and D. R. Hopkins, pp. 145-155. Dahlem Workshop Report, J. Lupp, series ed. Chichester: John Wiley & Sons.
323. Taylor, S. 2009. Political epidemiology: Strengthening socio-political analysis for mass immunisation-lessons from the smallpox and polio programmes. Global Public Health 4(6):546-560.
324. Thompson, K. M., and R. J. Duintjer Tebbens. 2006. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Analysis 26(6):1423-1440.
325. Thompson, K. M., and R. J. Duintjer Tebbens. 2007. Eradication versus control for poliomyelitis: An economic analysis. Lancet 369(9570):1363-1371.
326. Thompson, K. M., and R. J. Duintjer Tebbens. 2008a. The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation. Medscape J. Med. 10(8):190.
327. Thompson, K. M., and R. J. Duintjer Tebbens. 2008b. Using system dynamics to develop policies that matter: Global management of poliomyelitis and beyond. System Dynamics Rev. 24(4):433-449.
328. Thompson, K. M., R. J. Duintjer Tebbens, and M. A. Pallansch. 2006. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Analysis 26(6):1541-1556.
329. Thompson, K. M., R. J. Duintjer Tebbens, M. A. Pallansch, et al. 2008. The risks, costs, and benefi ts of global policies for managing polio after eradication. Am. J. Public Health 98(7):1322-30.
330. Thylfors, B., M. M. Alleman, and N. Twum-Danso. 2008. Operational lessons from 20 years of the Mectizan donation program for the control of onchocerciasis. Trop. Med. Intl. Health 13(5):689-696.
331. Tomori, O., C. Maher, S. Essien, et al. 2010. 19th Meeting of the expert review committee on polio eradication and routine immunization in Nigeria, 22-24 March 2010, Minna, Nigeria. http://www.comminit.com/fi les/FinalReport-19thERCMeeting.pdf (accessed 13 March 2011).
332. Travis, P., S. Bennett, A. Haines, et al. 2004. Overcoming health-systems constraints to achieve the Millennium Development Goals. Lancet 364(9437):900-906.
333. Ulmer, J. B., and M. A. Liu. 2002. Science and society-vaccines: Ethical issues for vaccines and immunization. Nat. Rev. Immun. 2:291.
334. UN. 1948. The Universal Declaration of Human Rights, Article 25. http://www.un.org/ en/documents/udhr/index.shtml (accessed 12 February 2011).
335. UN. 1966. International Covenant of Economic, Social and Cultural Rights (ICESCR), Article 12. http://www2.ohchr.org/english/law/cescr.htm (accessed 12 February 2011).
336. Unger, J.-P., P. De Paepe, and A. Green. 2003. A code of best practice for disease control programs to avoid damaging health care services in developing countries. Intl. J. Health Plan. Manag. 18:S27-S39.
337. UNICEF. 2010. Knowledge, Attitudes and Practices (KAP) on Polio "Plus" in the 107 High Risk Blocks of UP and Bihar, in press.
338. UNICEF, UNDP, World Bank, and WHO. 2008. Community-directed Interventions for Major Health Problems in Africa: A Multi-country Study. Special Program for Research and Training in Tropical Diseases. Geneva: WHO.
339. UNPD. 2009. World population prospects: The 2008 revision population database. http://esa.un.org/UNPP/ (accessed 27 January 2011).
340. U.S. FDA. 2009. What is a serious adverse event? MedWatch The FDA Safety Information and Adverse Event Reporting Program, http://www.fda.gov/Safety/ MedWatch/HowToReport/ucm053087.htm (accessed 3 November 2010).
341. U.S. Global Health Initiative. 2010. U.S. Global Health Initiative: Key Issues- Kaiser Family Foundation Policy Brief. http://www.kff.org/globalhealth/8063.cfm (accessed 23 November 2010).
342. van Hout, B. A. 1998. Discounting costs and effects: A reconsideration. Health Econ. 7(7):581-594.
343. Vashishtha, V. M. 2009. Why tuberculosis is a difficult disease to target for control or elimination? Indian J. Pediatr. 46:82-83.
344. Vashishtha, V. M., T. J. John, R. K. Agarwal, and A. Kalra. 2008. Universal immunization program and polio eradication in India. Indian J. Pediatr. 45(10):807-813.
345. Verwieji, M., and A. Dawson. 2004. Ethical principles for collective immunization programmes. Vaccine 22:3122-3126.
346. Vujicic, M. 2010. Scaling up the health workforce in the public sector: the role of government fi scal policy. World Hosp. Health Serv. 46(3):20-23.
347. Wakabi, W. 2009. Africa sees obstacles to guinea worm disease eradication. Lancet 373(9670):1159.
348. Wallace, A. 2005. Getting 1 + 1 to equal three: Best practices for maximizing benefi ts and overcoming barriers to the integration of lymphatic fi lariasis elimination with other health interventions in Tanzania. Unpublished masters thesis, Rollins School of Public Health, Global Health Department, Emory University, Atlanta.
349. Wallace, A., V. Dietz, and K. L. Cairns. 2009. Integration of immunization services with other health interventions in the developing world: What works and why? Systematic literature review. Trop. Med. Intl. Health 14(1-9).
350. Walsh, J. A., and K. S. Warren. 1979. Selective primary health care. N. Engl. J. Med. 301(18):967-974.
351. Walsh, J. A., and K. S. Warren. 1980. Selective primary health care: An interim strategy for disease control in developing countries. Soc. Sci. Med. 14(2):145-163.
352. Wassilak, S., and W. Orenstein. 2010. Challenges faced by the global polio eradication initiative. Expert Rev. Vaccines 9(5):447-449.
353. Weil, D. E. C. 2000. Advancing tuberculosis control within reforming health systems. Intl. J. Tuberc. Lung Dis. 4:597-605.
354. WHO. 1946. Constitution. http://www.who.int/governance/eb/constitution/en/index. html (accessed 12 February 2011).
355. WHO. 1978. Primary health care: Report on the international conference on primary health care, Alma-Ata, USSR. http://whqlibdoc.who.int/publications/9241800011. pdf (accessed 23 November 2010).
356. WHO. 1988. Global eradication of poliomyelitis by the year 2000. World Health Assembly Resolution 41.28. Geneva: WHO.
357. WHO. 1998. Global disease elimination and eradication as public health strategies. Bull. WHO 76(2):1-162.
358. WHO. 2000a. Preparing and implementing a national plan to eliminate lymphatic fi lariasis: A guideline for programme managers. http://www.fi lariasis.org/pdfs/ Press%20Centre/Training%20Material/pmginco.pdf (accessed 23 October 2010).
359. WHO. 2000b. The world health report 2000. Health systems: Improving performance. http://www.who.int/whr/2000/en/ (accessed 27 January 2011).
360. WHO. 2001a. Checklist and indicators for optimizing the impact of polio activities on EPI. http://www.polioeradication.org/content/publications/checklist_ optimizeactivities.pdf (accessed 23 November 2010).
361. WHO. 2001b. Macroeconomics and health: Investing in health for economic development. Report of the Commission on Macroeconomics and Health. http:// www.paho.org/English/HDP/HDD/Sachs.pdf (accessed 1 July 2010).
362. WHO. 2001c. Transmission of wild poliovirus type 2: Apparent global interruption. W. Epidem. Rec. 76:95-97.
363. WHO. 2002. Understanding barriers to polio eradication in Uttar Pradesh: Final report. http://www.comminit.com/en/node/220372/303 (accessed 23 November 2010).
364. WHO. 2003a. Global Polio Eradication Initiative: Estimated external fi nancial resource requirements 2004-2008. Geneva: WHO.
365. WHO. 2003b. SARS outbreak contained worldwide: Threat remains and more research needed, says WHO. http://www.who.int/mediacentre/news/releases/2003/ pr56/en/ (accessed 1 July 2010).
366. WHO. 2004. High-level forum on the health MDGs. www.who.int/hdp/en/summary. pdf (accessed 23 November 2010).
367. WHO. 2006a. Action against worms. Issue 6. http://www.who.int/wormcontrol/ newsletter/PPC6_Eng.pdf (accessed 23 October 2010).
368. WHO. 2006b. Opportunities for global health initiatives in the health systems action agenda, working paper 4. http://www.who.int/management/Making%20 HSWork%204.pdf (accessed 27 January 2011).
369. WHO. 2006c. Preventive chemotherapy in human helminthiasis. http://whqlibdoc. who.int/publications/2006/9241547103_eng.pdf (accessed 21 February 2011).
370. WHO. 2006d. Trachoma control: A guide for programme managers. http://whqlibdoc. who.int/publications/2006/9241546905_eng.pdf (accessed 23 October 2010).
371. WHO. 2006e. The world health report 2006: Working together for health. http://www. who.int/whr/2006/en/ (accessed 23 November 2010).
372. WHO. 2007a. Everybody's business: Strengthening health systems to improve health outcomes. WHO's Framework for Action. Geneva: WHO.
373. WHO. 2007b. Health of migrants: Report by the Secretariat, 20 December 2007. EB122/11. http://apps.who.int/gb/ebwha/pdf_fi les/EB122/B122_11-en.pdf (accessed 6 December 2010).
374. WHO. 2007c. Spending on health: A global overview. http://www.who.int/ mediacentre/factsheets/fs319/en/print.html (accessed 1 July 2010).
375. WHO. 2008a. Guide for standardization of economic evaluations of immunization programmes, WHO/IVB/08.14. http://whqlibdoc.who.int/hq/2008/WHO_ IVB_08.14_eng.pdf (accessed 1 July 2010).
376. WHO. 2008b. Thematic evaluation of poliomyelitis eradication. Executive Board of the World Health Assembly. Geneva: WHO.
377. WHO. 2008c. The World Health Report 2008. Primary health care, now more than ever. www.who.int/whr/2008/en/ (accessed 23 November 2010).
378. WHO. 2009. Measles vaccines: WHO position paper. W. Epidem. Rec. 35(89):349- 360.
379. WHO. 2010a. Global eradication of measles: Report of the Secretariat, WHO/A63/18. http://apps.who.int/gb/ebwha/pdf_fi les/WHA63/A63_18-en.pdf (accessed 1 July 2010).
380. WHO. 2010b. Global immunization vision and strategy. http://www.who.int/ immunization/givs/en/ (accessed 7 June 2010).
381. WHO. 2010c. Global Polio Eradication Initiative: Strategic Plan 2010-2012. WHO Document WHO/Polio/10.01. Geneva: WHO.
382. WHO. 2010d. Monitoring drug coverage for preventive chemotherapy. http:// whqlibdoc.who.int/publications/2010/9789241599993_eng.pdf (accessed 21 February 2011).
383. WHO. 2010e. Monitoring progress towards measles elimination. W. Epidem. Rec. 85:490-495.
384. WHO. 2010f. Outbreaks following importations of wild poliovirus into countries of the WHO African, European and South-East Asian Regions: January 2009- September 2010. W. Epidem. Rec. 85:445-452.
385. WHO. 2011. WHO African region: Nigeria. Expanded programme on immunization. http://www.who.int/countries/nga/areas/epi/en/index.html (accessed 2 January 2011).
386. WHO/APOC. 2007a. Revitalising health care delivery in sub-Saharan Africa: The potential of community-directed treatment to strengthen health systems. http://www. who.int/apoc/publications/EN_HealthCare07_7_3_08.pdf (accessed 17 February 2011).
387. WHO. 2007b. Year 2007 progress report of WHO/APOC. http://www.who.int/apoc/ publications/progress_report_jaf13_2007_en.pdf (accessed 18 February 2011).
388. WHO. 2009 Informal consultation on elimination of onchocerciasis transmission using current tools in Africa "Shrinking the Map." Ouagadougou, Burkina Faso, February 25-27, 2009
389. WHO Maximizing Positive Synergies Collaborative Group. 2009. An assessment of interactions between global health initiatives and country health systems. Lancet 373:2137-2169.
390. WHO Regional Office for Africa. 2007. In-depth evaluation of the reaching every district approach in the African region. http://www.who.int/immunization/sage/1_ AFRO_1_RED_Evaluation_Report_2007_Final.pdf (accessed 8 November, 2010).
391. WHO. 2010. Integration of child survival interventions with immunization services. http://www.afro.who.int/index.php?Itemid=2572 (accessed 1 August 2010).
392. WHO Strategic Advisory Group of Experts. 2010. Impact of new vaccines introduction on immunization and health systems. Report of an ad-hoc working group. http:// www.who.int/immunization/sage/NUVI_IS_HS_fi nal_Refs_12_April_2010.pdf (accessed 21 October 2010).
393. WHO/TDR. 2008. Community-directed interventions for major health problems in Africa: A multi-country study. Final report 2008. http://apps.who.int/tdr/ publications/tdr-research-publications/community-directed-interventions-healthproblems/ pdf/cdi_report_08.pdf (accessed 1 March 2011).
394. WHO, UNICEF, and World Bank. 2009. State of the World's Vaccines and Immunization, 3rd ed. Geneva: World Health Organization.
395. WHO, UNICEF., and USAID. 2000. Communication for routine immunization and polio eradication: A synopsis of fi ve sub-Saharan country case studies. http:// indexmedicus.afro.who.int/iah/fulltext/synopsis-fi vesubsaharan.pdf (accessed 27 January 2011).
396. Williams, G. A., and R. B. Miller. 2002. Change the way you persuade. Harvard Bus. Rev. May:65-73.
397. Windsor, D. A. 1998. Equal rights for parasites. Bioscience 48(4):244.
398. Woodward, D., and R. D. Smith. 2003. The global public goods for health concept. In: Global Public Goods for Health, ed. R. D. Smith et al. Oxford: Oxford Univ. Press.
399. World Bank. 1993. World Bank Development Report 1993: Investing in Health. New York: Oxford Univ. Press.
400. World Bank. 2007. Healthy development: The World Bank strategy for HNP results. http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION/ Resources/281627-1154048816360/HNPStrategyFINALApril302007.pdf (accessed 23 November 2010).
401. World Bank. 2011a. Global partnership to eliminate riverblindness. http://go.worldbank. org/F5NNFM6K40 (accessed 19 February 2011).
402. World Bank. 2011b. GNI per capita, Atlas method (current US$). http://data.worldbank.org/ indicator/NY.GNP.PCAP.CD (accessed 22 Jan 2010).
403. World Bank/APOC. 2010. Press Release No: 2011/239/AFR ABUJA, December 10, 2010. http://web.worldbank.org/WBSITE/EXTERNAL/COUNTRIES/AFRICAEX T/0,contentMDK:22788056~menuPK:2246551~pagePK:2865106~piPK:2865128 ~theSitePK:258644,00.html (accessed 17 February 2010).
404. World Economic Forum. 2009. Managing our future water needs. www.weforum.org/ pdf/water/WaterInitiativeGlance.pdf (accessed 27 January 2011).
405. World Health Assembly. 1988. Global Eradication of Poliomyelitis by the Year 2000, Resolution 41.28. Geneva: WHO.
406. Yahya, M. 2006. Polio vaccines - difficult to swallow: The story of a controversy in northern Nigeria. http://www.eldis.org/vfi le/upload/1/document/0708/DOC21227. pdf (accessed 27 January 2011).
407. Zimmerman, P. A., C. R. Katholi, M. C. Wooten, N. Lang-Unnasch, and T. R. Unnasch. 1994. Recent evolutionary history of American Onchocerca volvulus, based on analysis of a tandemly repeated DNA sequence family. Mol. Biol. Evol. 11(3):384- 392.